TipRanks
Evommune, Inc. (EVMN)
NYSE:EVMN
US Market
EVMN
Evommune, Inc.
RESEARCH TOOLSreports
Want to see EVMN full AI Analyst Report?

Evommune, Inc. (EVMN) Stock News & Sentiment

141 Followers
Evommune announces positive Phase 2a results for EVO301
Premium
Company Announcements
Evommune announces positive Phase 2a results for EVO301
20h ago
8K
EVMN
Evommune Highlights Positive EVO301 Atopic Dermatitis Phase 2a Data
Premium
Company Announcements
Evommune Highlights Positive EVO301 Atopic Dermatitis Phase 2a Data
8d ago
8K
EVMN
Evommune updates pipeline and market outlook in presentation
Premium
Company Announcements
Evommune updates pipeline and market outlook in presentation
17d ago
8K
EVMN
Evommune Shifts Atopic Dermatitis Focus to EVO301
Premium
Company Announcements
Evommune Shifts Atopic Dermatitis Focus to EVO301
23d ago
8K
EVMN
Analyst Initiates Buy on Evommune, Citing Strong EVO301 Proof-of-Concept and Upside Optionality from EVO756
Premium
Ratings
Analyst Initiates Buy on Evommune, Citing Strong EVO301 Proof-of-Concept and Upside Optionality from EVO756
1M ago
EVMN
Evommune Launches Phase 2b Trial for EVO756 Migraine Drug
Premium
Company Announcements
Evommune Launches Phase 2b Trial for EVO756 Migraine Drug
2M ago
8K
EVMN
Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study
Premium
Company Announcements
Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study
3M ago
EVMN
More EVMN News >

EVMN News on the Web

Evommune Highlights Positive EVO301 Atopic Dermatitis Phase 2a Data
TipRanks News
Neutral
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
Insider Monkey
Neutral
Evommune price target lowered to $23 from $28 at Clear Street
TipRanks News
Bearish
Evommune Shifts Atopic Dermatitis Focus to EVO301
TipRanks News
Neutral
Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints
TipRanks News
Bearish
Evommune down 31% at $9 after Phase 2b EVO-756 study results
TipRanks News
Neutral
Stifel Nicolaus Sticks to Their Buy Rating for Evommune, Inc. (EVMN)
TipRanks News
Neutral
Septerna price target lowered to $45 from $52 at Guggenheim
TipRanks News
Bearish

News Score - Last 7 Days

Neutral
EVMN
Sector Average
Media Buzz
This Week3 articles
Weekly Average5.25 articles
News Sentiment
This Week50%
Sector Average89%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

FAQ

What is EVMN’s Media Buzz Sentiment?
3 articles about EVMN were published this week. In an average week, 5.25 articles are published.
    What is EVMN’s weekly average amount of articles?
    In an average week, 5.25 articles about EVMN are published.
      What is EVMN’s News Sentiment?
      50% of articles about EVMN were positive this week, compared to its sector average of 89%.
        General Stocks that are Trending in the News
        RPDRapid7
        TERATera Yatirim Menkul Degerler AS
        R2PD34Rapid7 Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.083333 Sh
        T2TD34Trade Desk, Inc. Shs A Unsponsored Brazilian Depositary Receipt Repr 0.01 Sh A
        T1AM34Atlassian Corp Shs A Unsponsored Brazilian Depository Receipt Repr 0.05 Sh A
        Showing the stocks with the most bullish news sentiment over the past week